Veit L. Bücklein

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression

M. von Bergwelt-Baildon, M. Subklewe, V. Bücklein, 2021, Frontiers in Immunology.

Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy

P. Bartenstein, M. von Bergwelt-Baildon, J. Ricke, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Diagnosis of CLL revisited: increased specificity by a modified five‐marker scoring system including CD200

W. Hiddemann, K. Spiekermann, Z. Pasalic, 2017, British journal of haematology.

Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning—a matched pair analysis

R. Claus, A. Rank, S. Häbe, 2019, Annals of Hematology.

Sequential HLA‐haploidentical transplantation utilizing post‐transplantation cyclophosphamide for GvHD prophylaxis in high‐risk and relapsed/refractory AML/MDS

G. Ledderose, S. Haebe, C. Schmid, 2018, American journal of hematology.